Jack W Callicutt insider trades: Galectin Therapeutics (GALT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jack reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | GALT | ↓ Sell10b5-1 | 60,000 | $3.89 | $233K | Direct | Jan 6, 2026 (0d) |
| Nov 18, 2025 | GALT | ↓ Sell | 77,920 | $6.15 | $479K | Direct | Nov 19, 2025 (1d) |
| Nov 10, 2025 | GALT | ↓ Sell | 5,291 | $6.03 | $32K | Direct | Nov 12, 2025 (2d) |
| Nov 5, 2025 | GALT | ↓ Sell | 200 | $6.00 | $1K | Direct | Nov 7, 2025 (2d) |
| Nov 4, 2025 | GALT | ↓ Sell | 28,629 | $6.07 | $174K | Direct | Nov 5, 2025 (1d) |
| Nov 3, 2025 | GALT | ↓ Sell | 2,560 | $6.01 | $15K | Direct | Nov 5, 2025 (2d) |
| Nov 3, 2025 | GALT | ↓ Sell | 1,250 | $6.01 | $8K | Direct | Nov 5, 2025 (2d) |
| Sep 12, 2025 | GALT | ↓ Sell | 8,706 | $6.44 | $56K | Direct | Sep 15, 2025 (3d) |
| Dec 23, 2024 | GALT | ↓ Sell10b5-1 | 40,000 | $0.89 | $35K | Direct | Dec 26, 2024 (3d) |
| Nov 17, 2022 | GALT | ↑ Buy | 4,000 | $1.32 | $5K | Direct | Nov 17, 2022 (0d) |
| May 31, 2019 | GALT | ↑ Buy | 2,354 | $4.28 | $10K | Direct | Jun 3, 2019 (3d) |
| Jun 20, 2018 | GALT | ↓ Sell | 226,000 | $8.61 | $1.9M | Direct | Jun 21, 2018 (1d) |
| Jun 12, 2018 | GALT | ↓ Sell | 9,294 | $7.01 | $65K | Direct | Jun 14, 2018 (2d) |
| Jun 11, 2018 | GALT | ↓ Sell | 120,000 | $5.85 | $703K | Direct | Jun 12, 2018 (1d) |
| May 31, 2018 | GALT | ↓ Sell | 46,651 | $5.00 | $233K | Direct | Jun 4, 2018 (4d) |
| Apr 4, 2018 | GALT | ↓ Sell | 3,349 | $5.00 | $17K | Direct | Apr 6, 2018 (2d) |
| Aug 14, 2014 | GALT | ↑ Buy | 1,000 | $4.54 | $5K | Direct | Aug 15, 2014 (1d) |
| Nov 19, 2013 | GALT | ↑ Buy | 260 | $6.25 | $2K | Direct | Nov 19, 2013 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other GALT insiders
Open-market trades in the last 12 months
About Jack W Callicutt's insider trades
Jack W Callicutt is Chief Financial Officer at Galectin Therapeutics (GALT). Since Nov 19, 2013, Jack has reported 4 open-market purchases worth $22K and 14 sales worth $4.0M on SEC Form 4. In the last 12 months: 3 sales ($744K).
2 sales (7% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (18 filings), option exercises (12 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GALT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.